Professor of Surgery and Oncology, Medical College VA
General Surgery
Dr. Harry D. Bear, MD
|
|
Give Review
Dr. Harry D. Bear practices General Surgery. He researched medicine at Virginia Commonwealth University School of Medicine. He received awards:"Physicians Distinguished Clinician Award", "Top Cancer Doctors", "Best Bedside Manner (Oncology) Honorable Mention", "America's Top Doctors", "Americas Most Compassionate Doctors", "America's Top Doctors for Cancer", "Patients Choice Award", "Outstanding Alumnus Award", "Distinguished Investigator Lifetime Achievement Award", "Americas Top Doctors for Cancer", "Top Doc in Breast Health, for Breast Cancer Treatment", "Best Doctors in America, Surgical Oncology", "Greater Richmonds Best Doctors", "Sharon H. Kohlenberg Health Care Service Award", "Sigma Xi", "Phi Kappa Phi", "H. Hudnal Ware Award for Highest Honor Graduate", "Sandoz Award in Surgery", "A.D. Williams Award for First in Class", "Alpha Omega Alpha", "Lange Book Award", "Roche Award for Highest Score on National Boards", "Aubrey H. Straus Prize for Infection & Immunity", "Departmental High Honors", "Fellow", "Top Docs, Oncologic Surgery in Richmond Area", "Top Docs for Women in Richmond Area" and "Fellow (FACS)". Dr. Harry D. Bear is also a published physician. He has 41 publication published. The most recent publication is: A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688. He is registered with Medicare and accepts Medicare payments.
Publications
- A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688.
- Neoadjuvant plus adjuvant bevacizumab in early breast Cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.
- Expansion of melanoma-specific lymphocytes in alternate gamma chain cytokines: gene expression variances between T cells and T-cell subsets exposed to IL-2 versus IL-7...
- Adoptive cellular therapy of Cancer: exploring innate and adaptive cellular crosstalk to improve anti-tumor efficacy.
- Myeloid-derived suppressor cells enhance IgE-mediated mast cell responses.
- Intraoperative injection of radiocolloid for sentinel node biopsy in breast Cancer.
- Peripheral blood mononuclear cells of patients with breast Cancer can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloid-derived suppressor cells.
- Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast Cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
- The Role of Margin Status and Reexcision in Local Recurrence Following Breast Conservation Surgery.
- Resection of the primary tumor improves survival in metastatic breast Cancer by reducing overall tumor burden.
- Cutting Edge: Mast Cells Critically Augment Myeloid-Derived Suppressor Cell Activity.
- Insurance and inpatient care: Differences in length of stay and costs between surgically treated Cancer patients.
- Human dosimetry and preliminary tumor distribution of 18F-fluoropaclitaxel in healthy volunteers and newly diagnosed breast Cancer patients using PET/CT.
- A gene transcription signature of obesity in breast Cancer.
- Methyl Binding Domain Protein 2 (MBD2) Dependent Proliferation and Survival of Breast Cancer Cells.
- Activated NKT Cells and NK Cells Render T Cells Resistant to Myeloid-Derived Suppressor Cells and Result in an Effective Adoptive Cellular Therapy against Breast Cance...
- A signature of immune function genes associated with recurrence-free survival in breast Cancer patients.
- Ex vivo expansion of tumor-reactive T cells by means of bryostatin 1/ionomycin and the common gamma chain cytokines formulation.
- Neoadjuvant chemotherapy for operable breast Cancer: individualizing locoregional and systemic therapy.
- Effects of surgical excision on survival of patients with stage IV breast Cancer.
- Completion axillary lymph node dissection for breast Cancer: immediate versus delayed versus none.
- Signatures associated with rejection or recurrence in HER-2/neu-positive mammary Tumors.
- Measuring circulating tumor cells as a surrogate end point for adjuvant therapy of breast Cancer: what do they mean and what should we do about them?
- Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast Cancer: a National Cancer Institute conference.
- Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.
- Reaping the harvest from neoadjuvant therapy for breast Cancer: reducing morbidity with sentinel lymph node biopsy.
- Tumor bed boost omission after negative re-excision in Breast-conservation treatment.
- Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast Cancer:National Surgical Adjuvant Breast...
- Sentinel node micrometastases and non-sentinel nodes in breast Cancer: how much do we need to know?
- Walter Lawrence, Jr.: a tribute to a surgical oncologist. "Been there, done that".
- Sentinel node biopsy after neoadjuvant chemotherapy in breast Cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
- Breast conservation therapy rates are no different in medically indigent versus insured patients with early stage breast Cancer.
- The impact of physician and hospital volume on the quality of surgical outcomes.
- Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast Cancer: the potential and the questions.
- Partial Breast brachytherapy after lumpectomy: low-dose-rate and high-dose-rate experience.
- Taking action on the volume-quality relationship: how long can we hide our heads in the colostomy bag?
- Earlier chemotherapy for breast Cancer: perhaps too late but still useful.
- Sentinel node mapping identifies vaccine-draining lymph nodes with tumor-specific immunological activity.
- Collaborative Initiatives in the Care of Early Stage Breast Cancer: Reduction in Variation of Breast-Conserving Therapy.
- Near-Infrared Imaging of Adoptive Immune Cell Therapy in Breast Cancer Model Using Cell Membrane Labeling.
Schools
Virginia Commonwealth University School Of Medicine
Peter Bent Brigham Hospital
Brigham Womens Hospital
Med College Va
Procedures Preformed
- Biopsy of Breast
- Breast Reconstruction
- Colectomy
- Excision of Breast Tumor
- View All
Conditions Treated
- Anal and Rectal Cancer
- Appendicitis
- Atelectasis
- Breast Cancer
- View All
Doctors Specialties
- General Surgery
Accepted Insurances
Awards
- Physicians Distinguished Clinician Award
- Top Cancer Doctors
- Best Bedside Manner (Oncology) – Honorable Mention
- America's Top Doctors
- America’s Most Compassionate Doctors
- America's Top Doctors for Cancer
- Patients’ Choice Award
- Outstanding Alumnus Award
- Distinguished Investigator Lifetime Achievement Award
- America’s Top Doctors for Cancer
- Top Doc in Breast Health, for Breast Cancer Treatment
- Best Doctors in America, Surgical Oncology
- Greater Richmond’s Best Doctors
- Sharon H. Kohlenberg Health Care Service Award
- Sigma Xi
- Phi Kappa Phi
- H. Hudnal Ware Award for Highest Honor Graduate
- Sandoz Award in Surgery
- A.D. Williams Award for First in Class
- Alpha Omega Alpha
- Lange Book Award
- Roche Award for Highest Score on National Boards
- Aubrey H. Straus Prize for Infection & Immunity
- Departmental High Honors
- Fellow
- Top Docs, Oncologic Surgery in Richmond Area
- Top Docs for Women in Richmond Area
- Fellow (FACS)
Education
-
Brigham and Women's Hospital -
Virginia Commonwealth University School of Medicine
Drug Facts
| NPI NUMBER | 1508950825 | |
| NPPES Provider LastName | BEAR | |
| NPPES Provider FirstName | HARRY | |
| NPPES Provider ZIPCode | 232985051 | |
| NPPES Provider State | VA | |
| Specialty Description | Surgical Oncology | |
| Total Claim Count | 190.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1508950825 |
| Last Name Of The Provider | BEAR |
| First Name Of The Provider | HARRY |
| View All |
Similar Doctors
|
|
Dr. Stephanie R. Goldberg, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Peter W. Brown, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul A. Ghaemmaghami, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Brennan J. Carmody, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Matthew L. Brengman, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Eric P. Melzig, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. David W. Galpern, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brian J. Kaplan, MD |
|
|
Dr. Marc P. Posner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carly A. Allred, MD |
|
|
Dr. Alok Dash, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kanayo K. Okafor, MD |
|
|
Dr. Keri E. Quinn, MD |